Satsuma Pharmaceuticals (Satsuma Pharmaceuticals) Operating Income : $-54.44 Mil (TTM As of Mar. 2023)

View and export this data going back to 2019. Start your Free Trial

What is Satsuma Pharmaceuticals Operating Income?

Satsuma Pharmaceuticals's Operating Income for the three months ended in Mar. 2023 was $-10.77 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Mar. 2023 was $-54.44 Mil.

Operating Margin % is calculated as Operating Income divided by its Revenue. Satsuma Pharmaceuticals's Operating Income for the three months ended in Mar. 2023 was $-10.77 Mil. Satsuma Pharmaceuticals's Revenue for the three months ended in Mar. 2023 was $0.00 Mil. Therefore, Satsuma Pharmaceuticals's Operating Margin % for the quarter that ended in Mar. 2023 was %.

Satsuma Pharmaceuticals's 5-Year average Growth Rate for Operating Margin % was 0.00% per year.

Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Satsuma Pharmaceuticals's annualized ROC % for the quarter that ended in Mar. 2023 was -4,486.67%. Satsuma Pharmaceuticals's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2023 was -43,343.16%.

Satsuma Pharmaceuticals Operating Income Historical Data

The historical data trend for Satsuma Pharmaceuticals's Operating Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Satsuma Pharmaceuticals Operating Income Chart

Satsuma Pharmaceuticals Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Operating Income

Get a 7-Day Free Trial

-7.52

-28.88

-48.33

-51.17

-59.22

Satsuma Pharmaceuticals Quarterly Data
	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23
Operating Income	Get a 7-Day Free Trial															-15.55	-16.40	-15.41	-11.86	-10.77

Satsuma Pharmaceuticals Operating Income Calculation

Operating Income, is the profit a company earned through operations. All expenses, including cash expenses such as cost of goods sold (COGS), research & development, wages, and non-cash expenses, such as depreciation, depletion and amortization, have been deducted from the sales.

Operating Income for the trailing twelve months (TTM) ended in Mar. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-54.44 Mil.

Satsuma Pharmaceuticals (NAS:STSA) Operating Income Explanation

1. Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Satsuma Pharmaceuticals's annualized ROC % for the quarter that ended in Mar. 2023 is calculated as:

	ROC % (Q: Mar. 2023 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Dec. 2022 )	+	Invested Capital (Q: Mar. 2023 ))	/ count )
=	-43.072 * ( 1 - 0% )	/	( (0.337	+	1.583)	/ 2 )
=	-43.072	/	0.96
=	-4,486.67 %

where

	Invested Capital		(Q: Dec. 2022 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	54.939	-	7.908	-	( 52.481	-	max(0, 8.115	-	54.809	+	52.481	))
=	0.337

	Invested Capital		(Q: Mar. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	43.479	-	4.352	-	( 41.37	-	max(0, 5.831	-	43.375	+	41.37	))
=	1.583

Note: The Operating Income data used here is four times the quarterly (Mar. 2023) data.

2. Joel Greenblatt's definition of Return on Capital:

Satsuma Pharmaceuticals's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2023 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Mar. 2023 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Dec. 2022		Q: Mar. 2023
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	-41.176	/	( ( (0.108 + max(-5.649, 0))	+	(0.082 + max(-3.71, 0)) )	/	2 )
=	-41.176	/	( ( 0.108	+	0.082 )	/	2 )
=	-41.176	/	0.095
=	-43,343.16 %

where Working Capital is:

	Working Capital		(Q: Dec. 2022 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0	+	2.328)	-	(7.908	+	0	+	0.068999999999999)
=	-5.649

	Working Capital		(Q: Mar. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0	+	2.005)	-	(4.352	+	0	+	1.363)
=	-3.71

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2023) EBIT data.

3. Operating Income is also linked to Operating Margin %:

Satsuma Pharmaceuticals's Operating Margin % for the quarter that ended in Mar. 2023 is calculated as:

Operating Margin %	=	Operating Income (Q: Mar. 2023 )	/	Revenue (Q: Mar. 2023 )
	=	-10.768	/	0
	=	%

4. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Operating Income growth rate using Operating Income per share data.

Be Aware

Compared with a company's EBITDA margin, Operating Margin can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin may decline. Often the Operating Margin declines well before the company's revenue or even profit decline. Therefore, Operating Margin is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia's Operating Margin had already been in decline since 2002, although its earnings per share were still rising. Investors who paid attention to Operating Margin would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.

Satsuma Pharmaceuticals Operating Income Related Terms

Thank you for viewing the detailed overview of Satsuma Pharmaceuticals's Operating Income provided by GuruFocus.com. Please click on the following links to see related term pages.

Satsuma Pharmaceuticals (Satsuma Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Satsuma Pharmaceuticals Inc (NAS:STSA) » Definitions » Operating Income

Comparable Companies

Traded in Other Exchanges

N/A

Address

400 Oyster Point Boulevard, Suite 221, South San Francisco, CA, USA, 94080

Website

https://www.satsumarx.com

Satsuma Pharmaceuticals Inc is a clinical-stage biopharmaceutical company engaged in developing a novel therapeutic product for the treatment of migraine. Its product candidate, STS101, is a drug-device combination of a dry-powder formulation of dihydroergotamine mesylate, or DHE, which can be self-administered with a pre-filled, single-use, nasal delivery device.

Executives

Mutya Harsch	director	C/O FOAMIX PHARMACEUTICALS LTD., 2 HOLZMAN STREET, WEIZMANN SCIENCE PARK, REHOVOT L3 76704
Shin Nippon Biomedical Laboratories, Ltd.	10 percent owner	2438 MIYANOURA-MACHI, KAGOSHIMA CITY, KAGOSHIMA M0 891-1394
Thomas P Soloway	director	C/O AUDENTES THERAPEUTICS, INC., 600 CALIFORNIA ST., 17TH FLOOR, SAN FRANCISCO CA 94108
Ken Takanashi	director, 10 percent owner	C/O WAVE LIFE SCIENCES LTD., 733 CONCORD AVE., CAMBRIDGE MA 02138
Braden Michael Leonard	10 percent owner	156 S. FIRST STREET, ZIONSVILLE IN 46077
Commodore Capital Lp	10 percent owner	444 MADISON AVENUE, 35TH FLOOR, NEW YORK NY 10022
Ra Capital Healthcare Fund Lp	director, 10 percent owner	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Peter Kolchinsky	director, 10 percent owner	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Ra Capital Management, L.p.	director, 10 percent owner	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Detlef Albrecht	officer: Chief Medical Officer	SATSUMA PHARMACEUTICALS, INC., 400 OYSTER POINT BOULEVARD, SUITE 221, SOUTH SAN FRANCISCO CA 94080
Thomas P. O'neil	officer: Chief Financial Officer	SATSUMA PHARMACEUTICALS, INC., 400 OYSTER POINT BOULEVARD, SUITE 221, SOUTH SAN FRANCISCO CA 94080
Rajeev M. Shah	director, 10 percent owner	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Tpg Group Holdings (sbs) Advisors, Inc.	10 percent owner	C/O TPG GLOBAL, LLC, 301 COMMERCE STREET, SUITE 3300, FORT WORTH TX 76102
Heath Lukatch	director	326 BOLLAY DRIVE, GOLETA CA 93117
John A Kollins	director, officer: President and CEO	SATSUMA PHARMACEUTICALS, INC., 400 OYSTER POINT BOULEVARD, SUITE 221, SOUTH SAN FRANCISCO CA 94080